Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - Results of the randomised GeparQuinto study (GBG 44)

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - Results of the randomised GeparQuinto study (GBG 44)

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 49, Issue 10, July 2013, Pages 2284-2293

Jens Huober, Peter A. Fasching, Claus Hanusch, Mahdi Rezai, Holger Eidtmann, Kornelia Kittel, Jörn Hilfrich, Kathrin Schwedler, Jens-Uwe Blohmer, Hans Tesch, Bernd Gerber, Cornelia Höß, Sherko Kümmel, Christine Mau, Christian Jackisch,